UCLA

Patients with acute myeloid leukemia (AML) who achieve complete remission (CR) following induction therapy but continue to have measurable residual disease (MRD) have inferior outcomes following allogeneic hematopoietic cell transplant (alloHCT). Determining the historical rate of MRD clearance in response to standard consolidation therapy is needed as an initial step in developing a new therapeutic strategy to clear MRD prior to alloHCT. A multi-institution retrospective analysis was performed on 83 consecutively treated AML patients in morphologic complete remission (CR) with detectable MRD post-induction therapy who received standard chemotherapy consolidation from January 2016 to December 2021. In response to consolidation therapy, 27 of the 83 patients had MRD eliminated (33%) after all given cycles of consolidation cytarabine. Multivariable logistic regression showed that, when controlling for age, higher ELN risk category, higher dose of cytarabine, or more cycles of consolidation did not affect the likelihood of MRD conversion.